Data on this page show the responses of all individuals who received a Pfizer bivalent BA.1 COVID-19 vaccine and completed an AusVaxSafety survey sent on day 3 after vaccination. Note: The Pfizer bivalent BA.1 COVID-19 vaccine is no longer being administered in Australia; therefore, Pfizer bivalent BA.1 COVID-19 vaccine safety data below are no longer updated. AusVaxSafety has retained the display of historical Pfizer BA.1 COVID-19 vaccine safety data as a reference.

AusVaxSafety's active vaccine safety surveillance system complements the TGA's enhanced safety surveillance activities. Find out more about how the TGA monitors the safety of COVID-19 vaccines and how you can report side effects on the TGA website.

Read more about how AusVaxSafety is conducting national COVID-19 vaccine safety surveillance in Australia here.

Links to further information on the expected profile for Pfizer bivalent BA.1 COVID-19 vaccine are available below: 

AusVaxSafety will continue to closely monitor the safety data of COVID-19 vaccines in use in Australia in conjunction with the TGA.

Last updated June 2024